Because of an aging population and decreasing case fatality rate from improved medical care, there will be increasing numbers of survivors of stroke and myocardial infarction.
See related article, p 3180. C ardiovascular disease (CVD) and cerebrovascular disease are a major cause of death and disability worldwide.
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or at high risk of developing CVD. 4, 5 During the study period, most guidelines (eg, the National Cholesterol Education Program [NCEP] Adult Treatment Panel III [ATP III], the AHA, and the Canadian Guidelines for the Management of Dyslipidemia and Hypertension) focused on LDL-cholesterol as the primary therapeutic target and recommend individualized treatment goals tailored to the estimated cardiovascular risk. 5, [10] [11] [12] [13] The AHA guidelines for secondary prevention of ischemic stroke recommend that patients with ischemic stroke or transient ischemic attack (TIA) with elevated cholesterol or comorbid coronary artery disease (CAD) should be otherwise managed according to NCEP III guidelines (class IA), for those with atherosclerotic TIA/stroke a target of 70 mg/dL is suggested to obtain maximum benefit (class IIa; level of evidence B). 5 Most recently, the AHA and American College of Cardiology recommended in 2013 that cholesterol therapy be switched from LDL target-based therapy to therapy based on provision to patient groups considered most likely to benefit. 14 However, despite the well-established efficacy of lipid-lowering therapy, limited data are available on guideline attainment among high-risk patients with and without preexisting CVD, particularly among patients with stroke and TIA. Our goal was to evaluate and compare differences in the attainment to the contemporary lipid guidelines, based on admission LDL testing, among unselected patients with history of TIA, stroke, diabetes mellitus, and, CAD admitted with acute ischemic stroke or TIA to participating institutions in the Get With The Guidelines (GWTG)-Stroke Program.
Methods

Population Target and Data Collection
We evaluated all patients with a TIA or stroke enrolled in the GWTGStroke from April 2003 to September 2012. Details of the GWTG-Stroke Program have been published elsewhere. 15, 16 In brief, participating hospitals enter clinical information in a Web-based management tool (Outcome Sciences Inc, Cambridge, MA). They also receive decision support and obtain feedback reports of their performance on quality measures. Hospitals were instructed to record data from consecutive stroke and TIA admissions. Case ascertainment was through clinical identification during hospitalization, retrospective identification by International Classification of Diseases-Ninth Revision codes, or both. The eligibility of each case was confirmed at chart review before abstraction. The Web-based system checks for data quality to ensure that the reported data are complete and internally consistent.
LDL cholesterol is one of the 7 core key performance measures of the GWTG-Stroke program 17 based on existing AHA/American Stroke Association and NCEP-ATP III guidelines and endorsed by the National Quality Forum. 5, 10 Trained personnel at each institution abstracted LDL and other lipid levels if measured using the internet-based tool using standardized data definitions and detailed coding instructions. We used a previously published algorithm to determine the prestroke NCEP-ATP III goal (Table I in the online-only Data Supplement). 18 Participants with missing LDL, high-density lipoprotein, or total cholesterol (n=10 336; 1.1%) and those with missing relevant clinical information (n=170 169; 15.7%) were excluded ( Figure I in the online-only Data Supplement) because these elements were necessary to determine the NCEP-ATP III goals. 10 We also excluded patients with high levels of triglycerides (>400 mg/dL) for preventing indirect calculation of LDL levels.
Exposure
All enrolled patients with a case index TIA/stroke were classified in the following groups: (1) preexisting TIA/stroke (group CVD), (2) preexisting CAD, (3) preexisting concomitant CVD and CAD, and (4) no preexisting CAD/CVD group including patients with no known history of TIA, stroke, or CAD. The latest group was stratified by diabetes mellitus.
Outcome Measures
The AHA and NCEP-ATP III guidelines in place at the time of the registries recommended the same target LDL for patients (<100 mg/ dL) for ischemic stroke or patients with TIA who have evidence of atherosclerosis. 10, 19 A lower target (<70 mg/dL) is recommended for high-risk patients to achieve a maximal benefit. 5 Adherence to NCEP-ATP III guidelines was recommended in the 2011 update of the AHA guidelines. 5 In this study, the primary outcome measure was attainment of the recommended LDL<100 mg/dL. Secondary outcomes included an LDL<70 mg/dL and meeting the NCEP III goals.
Statistical Analysis
The study population was stratified into 4 groups: (1) patients with preexisting cerebrovascular disease (TIA/stroke); (2) patients with preexisting CAD; (3) patients with concomitant preexisting CAD and CVD, and (4) patients with no history of CVD or CAD (no preexisting CAD/CVD group).
Percentages and mean (SD) were reported to describe distribution of categorical and continuous patient characteristics variables with normal distribution. For the continuous variables with skewed distribution, median (25th, 75th percentiles) were reported. Pearson χ 2 test and Kruskal-Wallis test were used to test difference across the patient groups for categorical and continuous variables, respectively. The trend in the use of lipid testing over time were tested using the Cochran-Mantel-Haenszel row-mean score test.
Multivariable logistic regression models were performed to determine the independent predictors of meeting LDL targets. The generalized estimating equations approach was used to account for within-hospital clustering. The covariates in the multivariable analysis included baseline patient characteristics age (as a continuous variable), sex, race/ethnicity (categorized as white, black, Hispanic, or other), comorbid conditions (atrial fibrillation, prosthetic heart valve, carotid stenosis, diabetes, peripheral vascular disease, hypertension, dyslipidemia, and smoking), year of enrollment, and hospital characteristics (bed size, annual number of stroke discharges, academic teaching status, and geographical region). Hospital bed size was entered as a continuous variable, whereas annual number of stroke discharges were categorized as 0 to 100, 101 to 300, or >300. Hospital teaching status and hospital region (defined as Northeast, Midwest, South, or West) were determined using statistics published by the American Hospital Association. 20 All P values were 2-sided, with P value <0.05 considered statistically significant. Analyses were performed using SAS version 9.2 software (SAS Institute, Cary, NC).
Each participating hospital received institutional review board approval to enroll participants without individual patient consent under the common rule or a waiver of authorization and exemption. Outcome Sciences, Inc, serves as the data collection and coordination center for GWTG. The Duke Clinical Research Institute was responsible for data analysis. 
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Dyslipidemia was observed in 42.9% of patients and 41.8% were receiving lipid-lowering therapy before the index event. Table 1 summarizes other demographic and baseline characteristics. The mean (±SD) LDL was 111.0 (±38), 100.9 (±38), 95.1 (±39), and 93.5 (±39) mg/dL in no patients with preexisting CAD/CVD (without history of CAD, CVD, or diabetes mellitus) and those with preexisting CVD, CAD, and both, respectively.
Outcome Measures
Although 47.6% of patients with preexisting TIA/stroke were receiving cholesterol-lowering agents, only 54.5% met the LDL<100 mg/dL target and only 21.4% met the LDL<70 mg/ dL target (Table 2) . Similarly, although 59.7% of patients with stroke and preexisting CAD were receiving cholesterol-lowering agents, only 62.3% and 28.5% met the LDL<100 and the LDL<70 mg/dL targets, respectively (Table 2; Figure) . Among patients with no preexisting CVD or CAD, even fewer had LDL<100 or <70 mg/dL (P<0.001; Table 2 ). Similarly, only approximately half of patients without preexisting vascular disease, but with diabetes mellitus, meet the NCEP-ATP III guidelines or meet an LDL<100 mg/dL. The use of statins was common after their new (index) ischemic stroke. Overall, 81% of patients were discharged on statins after their index hospitalization captured by GWTG-Stroke.
Men were more likely to meet the LDL targets compared with women. For example, 54.2% of men versus 48.6% of women met the LDL<100 mg/dL target (P<0.0001). Similarly, 22.1% of men versus 17.7% of women met the LDL<70 mg/dL target. (Table 3) .
We also observed better LDL control (LDL<100 mg/dL) over time ranging from 48.2% in 2006 to 59.3% in 2012 (P<0.0001) in patients with CVD (23.0% improvement) and from 57.4% to 65.9% (P<0.0001) for patients with preexisting CAD (14.8% improvement; Table 3 ). Despite the lower proportion of high-risk patients meeting LDL targets, greater improvements were observed during the study period. For example, there was a 58% relative improvement in the proportion of patients with preexisting TIA/stroke meeting LDL<70 mg/dL target in 2012 compared with 2006 (Table 3) .
Similar trends were observed in men, but control rates for LDL<100 mg/dL increased only in men, from 55.7% to 65.3% (P<0.0001; Table II in the online-only Data Supplement). White patients were more likely to meet LDL targets compared with black, Hispanic, and other race/ethnic group patients (Table 4 ). There was a sex by race interaction (P<0.0001) for all outcomes (Tables III and IV 
Multivariable Analysis
Multivariable analysis using generalized estimating equations to account for clustering revealed that older age, male sex, white race, presence of vascular risk factors (eg, history of atrial fibrillation, heart failure, carotid stenosis, and peripheral vascular disease), taking cholesterol-lowering agents before index event, later year enrollment, enrollment in larger 
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hospitals or hospitals located in the West or Midwest were all independently associated with a higher odds of meeting the LDL goals. The directions of the associations were consistent across all risk groups (data not shown). Multivariable-adjusted predictors of meeting LDL goals for patients with preexisting CVD and CAD are shown in Table 5 .
Discussion
In the present study, including >900 000 patients with an acute ischemic stroke admitted to participating institutions in the GWTG-Stroke, we evaluated attainment to the recommended LDL targets in 4 different groups: patients with stroke and previous TIA/stroke, patients with stroke and previous CAD/ myocardial infarction, patients with stroke and concomitant preexisting CAD and CVD, and patients without history of cardio-or cerebrovascular events. We found that only 21.4% of high-risk patients with preexisting TIA/stroke and 28.5% of patients with stroke and preexisting CAD, and 30.0% of patients with stroke and concomitant previous CVD and CAD met the current LDL recommended targets. Only half of patients with stroke with diabetes mellitus met the NCEP III guidelines, and 44% were taking cholesterol-lowering agents. Women and black patients presenting with an acute stroke and preexisting CAD or CVD were less likely to achieve the LDL targets when compared with men and white patients, respectively. High-risk patients with preexisting CAD compared with CVD alone were more likely to attain the LDL targets. We were also able to identify independent factors associated with attainment to the LDL guidelines among high-risk patients with preexisting TIA/ stroke and CAD, including older age, male sex, whites or white race, lack of vascular risk factors (except for atrial fibrillation), being on lipid-lowering agents before index event, enrollment in the latest years, and admissions to hospitals located in the West or Midwest or larger institutions.
Large epidemiological studies showed an increased risk of ischemic stroke among patients with dyslipidemia. According to several meta-analyses, including >90 000 patients included in statin trials, the larger the reduction in LDL, the greater the reduction in stroke risk. 7, 21 Most guidelines in place during the study period (eg, NCEP, AHA, and Canadian guidelines for the management of dyslipidemia) recommended LDL-cholesterol lowering as the primary lipid target. 5, 10, 12 The cardiovascular risk reduction is more noticeable for high-risk patients, usually defined as those with preexisting CVD or coronary heart equivalents (NCEP). 10 Our study occurs in the context of a new revision to the guideline-recommended approach to lipid management. The AHA and American College of Cardiology, carrying on the work of ATP IV, has recently issued its recommendations that includes changes to the principles of lipid management. 14 The new guidelines abandon LDL-targeted treatment in favor of directing fixed dose high-or moderate intensity statin therapy to patient groups considered likely to benefit based on randomized controlled trial evidence: (1) history of symptomatic CVD include stroke or TIA of atherosclerotic origin, (2) LDL≥190 mg/dL, (3) diabetes mellitus age 40 to 75 years with LDL≥70 mg/dL, or (4) estimated 10-year risk of myocardial infarction or stroke ≥7.5% based on new Pooled Cohort Equations.
Although the new guidelines 14 base treatment eligibility on predicted future risk from the pooled cohort equations, rather than LDL cutoffs, cholesterol levels still figure in the pooled cohort calculations. We may see a widening of the gap between guideline-recommended and actual practice, depending on the degree to which the controversy surrounding the new guidelines is resolved. In addition, there are large-scale clinical trials in progress evaluating new LDL-lowering agents that have enrollment criteria based on LDL levels achieved or not achieved with statin therapy. Should one or more of these trials prove to be positive, revisions to the guidelines would be expected. Thus, our study provides an assessment of the real-world success of guideline-based cholesterol management in high-risk patients-those hospitalized with a new ischemic stroke-in the time period when recommendations were based on LDL goal achievement based on risk group. We are not able to determine retroactively how many patients were treated according to new guideline specifications because the GWTG-Stroke database did not previously collect information on cholesterol-lowering drug class and dose intensity and contains insufficient information to calculate the predicted risk according to the Pooled Cohort Equation. However, it is clear that many patients with new ischemic stroke or TIA would have been considered insufficiently treated according to the new guidelines as well-for example, in 2011 to 2012 only 58% of patients with preexisting TIA or stroke and only 64% of patients with preexisting CAD were taking cholesterol-lowering drugs of any kind.
Previous studies conducted in different countries in the 1990s have also documented significant gaps between evidence-based medicine and real-world clinical practice. [22] [23] [24] [25] For example, among 4888 outpatients enrolled in the Lipid Treatment Assessment Project, overall only 38% attained the LDL-cholesterol goal recommended by NCEP-ATP II. A Canadian study including ≈5000 high-risk ambulatory patients with CAD, CVD, or both found that <25% met LDL-guideline-recommended targets. 26 A single-center study of hospitalized patients with ischemic stroke not only found higher attainment of prestroke LDL targets based on admission lipid testing (73%) but also found that higher risk patients, who had more stringent prestroke LDL targets, had the highest likelihood of not being at goal. 18, 27 The calculated cumulative risk reduction for implementing lifestyle modifications, antithrombotics, antihypertensive, and lipid-lowering therapy (all guideline-recommended strategies 
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in secondary stroke prevention) is 80%. 4 The results of this study highlight the substantial gap between current guidelines and target achievement in an outpatient setting. A few studies showed the importance of optimizing discharge planning for future adherence to the guidelines, 28, 29 but most of the studies were conducted in inpatient settings. For example, both The Reduction of Atherothrombosis for Continued Health (REACH) Registry and results from the GWTG revealed improvements in cholesterol testing over time and reducing ethnic and racial disparities. 18 A recent study including 1154 stroke survivors participating in The National Health and Nutrition Examination Surveys (1999-2010) revealed that cholesterol treatment rates increased from 30% to 40% in men (P=0.02) and from 28% to 36% (P<0.01) in women, but control rates increased only in men, from 62% to 87% (P<0.01). It is important to bear in mind that total cholesterol (defined as >5.2 mmol/L [>200 mg/dL]) was the therapeutic target. 30 Our study including >900 000 patients for a 9-year period revealed similar trends for each high-risk group. The finding that only 40% to 50% of high-risk patients were already on lipid-lowering agents at the time of the index event is concerning. However, most patients (80%) were discharged on statins after their new (index) ischemic stroke ( Table 2 ). The observed gap in LDL levels between patients with either preexisting stroke/TIA or no CVD and those with preexisting CAD could be explained by differences in the emphasis of recommended targets between cardiovascular and stroke prevention guidelines. 5, 6, 12 In addition, standard of care procedures more widely implemented for patients with CAD (ie, coronary revascularization) could improve patients' awareness and consequently treatment success. Together, these results suggest that clinicians may be more aggressive when facing older men with preexisting CVD or CAD with no vascular risk factors. Alternatively, socioeconomic, lifestyle behavior, and genetic factors may explain why ethnic groups other than whites, patients living in the northeast or south regions, or patients cared for in smaller hospitals were less likely to meet the LDL targets. Economic factors have also been documented in previous studies using hierarchical models. 31 The results of our study have practical clinical and policy implications. Several studies evaluating key process measures revealed that a high proportion of patients are discharged on lipid-lowering agents after a TIA/stroke. 18, 32, 33 The lower attainment to the LDL guidelines at the time of the index event for patients with preexisting CAD or CVD may suggest lower access or less aggressive ambulatory care in stroke prevention. New strategies may be needed to facilitate equal access to stroke prevention clinics, especially for high-risk groups. Outpatient adherence to evidence-based therapies should also be carefully and regularly assessed with close follow-up by the family physician, general practitioner, or specialists.
Several limitations deserve comment. We only included participating institutions in GWTG-Stroke, and our results may represent an underestimation of the low attainment to the lipid guidelines. Second, data were collected based on the medical record and may not be completely accurate if clinical documentation was incomplete. Third, LDL-measurements were not performed in a central core laboratory. However, this reflects real-world practice where physicians initiate or titrate therapy based on available test results. Fourth, we were unable to distinguish the subtype of a history of stroke (eg, between preexisting hemorrhagic stroke versus stroke because of carotid stenosis), to allow us estimate the NCEP goals for CVD patients (online-only Data Supplement). Fifth, the database does not contain information on prestroke cholesterol drug class or dose. Finally, cholesterol levels were obtained after onset of stroke and TIA, which may lower levels because of acute phase response. However, this unlikely to have changed the results because blood samples were likely obtained in first 24 hours. In addition, we note that our findings are relevant only to stroke and patients with TIA and are probably not representative of cholesterol levels in the general population.
Despite these limitations, our study constitutes the first step in understanding the differential gaps in ambulatory management of high-risk patients with preexisting cerebrovascular disease. This large study is unique in providing evidence those high-risk patients with preexisting CVD alone or concomitant CVD and CAD received suboptimal therapy. Only 1 in 4 of those patients met the LDL<70 mg/dL. Only half of patients with stroke and diabetes mellitus met LDL<100 mg/dL at the time of admission. In addition, women with CVD are less likely to achieve the lipid targets. Current management of dyslipidemia after a TIA/stroke remains suboptimal, despite a high proportion of individuals being discharged on lipid-lowering agents after their acute hospitalization for ischemic stroke. Quality improvement strategies should be directed to facilitate access to ambulatory care for high-risk patients with preexisting CVD, in particular, for those who are less likely to achieve the recommended targets. Missing LDL, HDL or total cholesterol n= 487,146 Table I . Algorithm for determining whether the patient is at their NCEP-ATPIII LDL goal
To determine whether a patient is at their NCEP-ATPIII-defined LDL goal 1 , a 3 step process is required: 1. Calculate the goal for that patient ("goal LDL"). The goal varies by patient and depends on their age and other risk factors. 2. Determine the patient's LDL level 3. Determine whether the patient's LDL level is higher or lower than their goal LDL.
Determining the NCEP-ATPIII goal: We have previously used GWTG-derived data to determine the NCEP ATPIII goal. 1 Essentially, the individual LDL goal depends on 3 items that are related to cardiovascular risk:
1. The presence/absence of major risk factors, called "coronary heart disease (CHD) equivalents" 2. The presence/absence of specified cardiovascular risk factors those are important, but not as critical as the CHD equivalents. 3. The 10-year predicted probability of heart attack calculated using the Framingham prediction rule.
CHD risk equivalents, in terms of GWTG variables, are:
• • HDL≥60 is a negative risk factor that counts as -1, that is, it subtracts another risk factor
The NCEP-ATPIII guidelines list family history of premature CHD as a Risk Factor; these data are not collected in GWTG. Therefore the LDL goal derived from the GWTG data is an estimate only, and it must be acknowledged that a few patients may have an estimated LDL goal that is different from the real LDL goal. Additionally, the LDL goal cannot be calculated in GWTG patients without measured HDL and total cholesterol.
The Framingham risk scoring system is used to calculate the "10-yr risk" as a percentage. GWTG data was used to determine the scoring risk, with the following caveats and modifications: Systolic blood pressure is not systematically captured in GWTG. Because of this we use a previously published modification of the Framingham risk score as follows: 
